Metastatic Merkel Cell Carcinoma Clinical Trial
Official title:
Temporary Authorization for Use (ATU) to Avelumab for Treatment of Adult Patients With Metastatic Merkel Cell Carcinoma (mMCC)
Expanded access to Avelumab solution for infusion will be made available for adult patients with mMCC whose disease has progressed after receiving at least one prior chemotherapy.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04261855 -
Targeted Therapy and Avelumab in Merkel Cell Carcinoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03816332 -
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
|
Phase 1 | |
Recruiting |
NCT05947500 -
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
|
Phase 2 | |
Recruiting |
NCT05269381 -
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03304639 -
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03599713 -
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
|
Phase 2 | |
Recruiting |
NCT05896839 -
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
|
Phase 1/Phase 2 |